ClinicalTrials.gg
Active, not recruitingNCT06101342PURPOSE 4Updated Aug 13, 2026

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

A Phase 2 interventional study of Lenacapavir Injection and Lenacapavir Tablet in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies in HIV Infections by Gilead Sciences — 2 open to participants now, 8 under way, 4 of them phase 3. HIV Infections · Gilead Sciences.

Enrollment
29th of 72
181 · median 131
Started
2023
with 1 other
Phase 2
16 of 84
none open now
Registered
80th of 84
by date

Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 29th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2023, is one of 16 in phase 2, and was the 80th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 84 studies in HIV Infections by Gilead Sciences are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in HIV Infections by Gilead Sciences, or all of them as a file.
02

Study summary

The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US).

The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.

03

Conditions studied

  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Urine drug screen positive for any drug of misuse including, but not limited to, opioids (eg, fentanyl, heroin), stimulants (eg, cocaine, amphetamines), psychoactive drugs (eg, benzodiazepines), or a combination of these drugs.
  • Evidence of recent injection (eg, track marks).
  • Self-report of injection paraphernalia sharing in the prior 30 days.
  • virus (HBV) surface antigen (HBsAg) negative.
  • Negative local rapid -1/2 antibody (Ab)/antigen (Ag) test, central HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated (GFR) at least 60 mL/min at screening according to the formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

  • Self-reported history of previous positive results on an HIV test.
  • Any reactive or positive HIV test result at screening or enrollment, even if HIV infection is not confirmed.
  • Coenrollment in any other interventional research study or other concurrent studies that may interfere with this study (as provided by self-report or other available documentation) without prior approval from the Medical Monitor/Joint Clinical Management Committee while participating in this study.
  • Past or current participation in HIV vaccine or HIV broadly neutralizing antibody study unless individual provides documentation of receipt of placebo (ie, not active product).
  • Prior use of long-acting systemic pre-exposure prophylaxis (PrEP) (including cabotegravir (CAB) or islatravir studies).
  • Acute viral hepatitis A or acute or chronic hepatitis B or C infection.
  • Have a suspected or known active, serious infection(s) (eg, active tuberculosis, etc).
  • Evidence of moderate or severe liver fibrosis or a history of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, variceal bleeding). In individuals with active , Fibrosis-4 (FIB-4) score > 3.25 (formula provided below).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Randomized Phase: Lenacapavir (LEN) Group

    Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.

    Drug: Lenacapavir Injection · Drug: Lenacapavir Tablet

  • Experimental
    Randomized Phase: Emtricitabine/ Tenofovir Disoproxil Fumarate (F/TDF) Group

    Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.

    Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

  • Experimental
    Open-label Extension Phase: LEN

    Participants randomized to LEN in the Randomized Phase who choose to participate in the LEN Open-Label Extension (OLE) Phase will receive SC LEN every 26 weeks (± 7 days) and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF in the Randomized Phase who choose to participate in LEN OLE Phase will switch to SC LEN and have study visits at LEN OLE Day 1, Week 4 (± 2 days), Week 13 (± 7 days), and every 13 weeks (± 7 days) thereafter. SC LEN will be administered at the LEN OLE Day 1 visit and every 26 weeks thereafter. These participants will also receive loading doses of oral LEN on OLE Days 1 and 2. Upon completion of the LEN OLE Phase, participants will transition to local HIV prevention services and return for a 30-day follow-up visit. At that time, participation in the study will end.

    Drug: Lenacapavir Injection · Drug: Lenacapavir Tablet

  • Experimental
    Pharmacokinetic (PK) Tail Phase: F/TDF

    Participants eligible for the PK Tail Phase will receive open-label oral F/TDF once daily for up to 78 weeks and complete study visits every 13 weeks (± 7 days). PK Tail Day 1 visit will occur 26 weeks (± 7 days) after the last SC LEN injection.

    Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

Interventions

  • Administered subcutaneously

    Also known as: GS-6207, Yeztugo®

  • Administered orally

    Also known as: GS-6207

  • DrugEmtricitabine/tenofovir disoproxil fumarate (F/TDF)

    Administered orally

    Also known as: Truvada®

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26)

    Time frame: Week 26

  2. PK Parameter: Ctrough for LEN: LEN Plasma concentration at the End of the Dosing Interval (Week 52)

    Time frame: Week 52

  3. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 30 days post last dose at Week 52

  4. Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities with LEN and F/TDF

    Time frame: First dose date up to 30 days post last dose at Week 52

Secondary outcomes

  1. General Acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Acceptability Questionnaire Responses

    To assess the acceptability of the study drug, the participants will complete questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale with a response of: Completely unacceptable, Unacceptable, No opinion, Acceptable, or Completely acceptable.

    Time frame: Up to Week 52

  2. Satisfaction With Use of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Satisfaction Questionnaire Responses

    To assess the satisfaction with use of the study drug, the participants will complete questionnaire including a question on satisfaction with use of the assigned study drug on an ordinal 5-category scale with a response of: Very satisfied, Satisfied, Neutral, Dissatisfied, or Very dissatisfied.

    Time frame: Up to Week 52

  3. Willingness to Use LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Willingness to Use Questionnaire Responses

    To assess the willingness to use the study drug, the participants will complete questionnaire including a question on willingness to use the assigned study drug on an ordinal 5-category scale with a response of: Definitely Yes, Probably yes, Not sure/undecided, Probably No, or Definitely No.

    Time frame: Up to Week 52

  4. Number of Participants with Adherence to LEN, as Assessed by On-time LEN Injections Received

    Time frame: Up to Week 26

  5. Number of Participants with Adherence to F/TDF as Assessed by Adherence Levels Based on Intracellular Tenofovir-diphosphate (TFV-DP) Concentrations in Dried Blood Spot (DBS)

    Time frame: Up to Week 78

07

Study locations

9 sites
  • UCLA Vine Street Clinic
    Los Angeles, California 90038, United States
  • UCSD AntiViral Research Center (AVRC)
    San Diego, California 92103, United States
  • University of Miami - Converge Miami Building
    Miami, Florida 33136, United States
  • Johns Hopkins Medicine Institute for Clinical and Translational Research, Clinical Research
    Baltimore, Maryland 21287, United States
  • Rutgers New Jersey Medical School, Department of Medicine
    Newark, New Jersey 07103, United States
  • ICAP at Columbia University- Bronx Prevention Center
    The Bronx, New York 10451, United States
  • University of Pennsylvania, Division of Infectious Diseases Penn Prevention Research Unit
    Philadelphia, Pennsylvania 19104, United States
  • Houston AIDS Research Team CRS
    Houston, Texas 77030, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
08

References and documents

Publications

  • Martinez S, Garcia-Romeu A, Wisdom J, Jones J. Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization. AIDS Care. 2026 Apr;38(4):856-869. doi: 10.1080/09540121.2025.2611079. Epub 2026 Jan 7. PubMed 41498432 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jul 2026, 31 months.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 26, 2023
StartActual
Dec 13, 2023
Primary completionActual
Jul 27, 2026
CompletionEst.
Jan 2028
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06101342
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Dec 13, 2023
Primary completion
Jul 27, 2026
Completion
Jan 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenacapavir

Start the discussion